1oum: Difference between revisions
No edit summary |
No edit summary |
||
Line 1: | Line 1: | ||
[[Image:1oum.gif|left|200px]] | [[Image:1oum.gif|left|200px]] | ||
<!-- | |||
The line below this paragraph, containing "STRUCTURE_1oum", creates the "Structure Box" on the page. | |||
You may change the PDB parameter (which sets the PDB file loaded into the applet) | |||
or the SCENE parameter (which sets the initial scene displayed when the page is loaded), | |||
or leave the SCENE parameter empty for the default display. | |||
--> | |||
{{STRUCTURE_1oum| PDB=1oum | SCENE= }} | |||
}} | |||
'''M64V PNP +Talo''' | '''M64V PNP +Talo''' | ||
Line 35: | Line 32: | ||
[[Category: Secrist, J A.]] | [[Category: Secrist, J A.]] | ||
[[Category: Sorscher, E J.]] | [[Category: Sorscher, E J.]] | ||
[[Category: | [[Category: M64v]] | ||
[[Category: | [[Category: Pnp]] | ||
[[Category: | [[Category: Talo]] | ||
''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Sat May 3 04:17:54 2008'' | |||
''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on |
Revision as of 04:17, 3 May 2008
M64V PNP +Talo
OverviewOverview
Activation of prodrugs by Escherichia coli purine nucleoside phosphorylase (PNP) provides a method for selectively killing tumor cells expressing a transfected PNP gene. This gene therapy approach requires matching a prodrug and a known enzymatic activity present only in tumor cells. The specificity of the method relies on avoiding prodrug cleavage by enzymes already present in the host cells or the intestinal flora. Using crystallographic and computer modeling methods as guides, we have redesigned E. coli PNP to cleave new prodrug substrates more efficiently than does the wild-type enzyme. In particular, the M64V PNP mutant cleaves 9-(6-deoxy-alpha-L-talofuranosyl)-6-methylpurine with a kcat/Km over 100 times greater than for native E. coli PNP. In a xenograft tumor experiment, this compound caused regression of tumors expressing the M64V PNP gene.
About this StructureAbout this Structure
1OUM is a Single protein structure of sequence from Escherichia coli. Full crystallographic information is available from OCA.
ReferenceReference
Designer gene therapy using an Escherichia coli purine nucleoside phosphorylase/prodrug system., Bennett EM, Anand R, Allan PW, Hassan AE, Hong JS, Levasseur DN, McPherson DT, Parker WB, Secrist JA 3rd, Sorscher EJ, Townes TM, Waud WR, Ealick SE, Chem Biol. 2003 Dec;10(12):1173-81. PMID:14700625 Page seeded by OCA on Sat May 3 04:17:54 2008